Lymphoma: Clinical Trials

Showing 1 - 50 of 68 trials
Title Investigatorsort icon
A Phase I/II Study of Sequential Chemoradiation Followed by Autologous Stem Cell Transplant in Patients with Untreated Advanced Mantle Cell Lymphoma
Newly Diagnosed
[Protocol 11-095]
Zelenetz, Andrew, MD, PhD
A Phase II Study of CAL-101 plus Rituximab in Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
[Protocol 10-224]
Zelenetz, Andrew, MD, PhD
A Phase Ib Study of Urelumab Given with Rituximab in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Relapsed/Refractory
[Protocol 13-252]
Zelenetz, Andrew, MD, PhD
A Phase I Study of CB-839 in Patients with Advanced or Persistent Hematologic Cancers
[Protocol 14-053]
Younes, Anas, MD
A Phase II Study of BKM120 in Patients with Recurrent or Persistent Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
[Protocol 13-072]
Younes, Anas, MD
A Phase III Study of Ibrutinib (PCI-32765) plus R-CHOP Chemotherapy in Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL)
[Protocol 13-146]
Younes, Anas, MD
A Phase I Study of CPI-0610 in Patients with Progressive Lymphoma
Relapsed/Refractory
[Protocol 13-259]
Younes, Anas, MD
A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Relapsed/Refractory
[Protocol 13-045]
Younes, Anas, MD
A Phase I Study of VS-5584 in Patients with Lymphoma or Advanced Solid Tumors
[Protocol 14-065]
Varghese, Anna, MD
A Phase I Study of SGN-CD19A in Children and Adults with Persistent B-Cell Acute Lymphoblastic Leukemia or Aggressive Non-Hodgkin Lymphoma
Relapsed/Refractory
[Protocol 13-106]
Trippett, Tanya, MD
A Phase I/II Study of Brentuximab (SGN-35) in Pediatric Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma or Hodgkin Lymphoma
Relapsed/Refractory
[Protocol 11-210]
Trippett, Tanya, MD
A Randomized Phase III Study of Standard Chemotherapy with and without Brentuximab in Patients Newly Diagnosed with Advanced Hodgkin Lymphoma
[Protocol 13-056]
Straus, David, MD
A Phase I Study of PF-05082566 Alone in Patients with Advanced Cancer, and in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma
[Protocol 11-085]
Segal, Neil, MD, PhD
A Phase I Study of High-Dose Therapy and Autologous Stem Cell Transplantation Followed by Modified T Cells for Aggressive B-Cell Non-Hodgkin Lymphoma
Relapsed/Refractory
[Protocol 12-117]
Sauter, Craig, MD
A Study of Allogeneic Stem Cell Transplantation in HIV-Infected Patients with Hematologic Cancers
[Protocol 12-092]
Sauter, Craig, MD
A Phase I/II Study Assessing BPX-501 T Cells Given After Partially Mismatched Related T Cell-Depleted Stem Cell Transplantation in Patients with Hematologic Cancers
[Protocol 13-181]
Perales, Miguel-Angel, MD
A Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin's Lymphoma
[Protocol 07-147]
Perales, Miguel-Angel, MD
A Phase I Study of IMGN529 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
[Protocol 13-073]
Palomba, M. Lia, MD
A Phase III Study of Rituximab/Lenalidomide or Rituximab/Chemotherapy Followed by Rituximab Maintenance Therapy in Patients with Previously Untreated Follicular Lymphoma
Newly Diagnosed
[Protocol 12-081]
Palomba, M. Lia, MD
A Phase II Study of Ibrutinib plus Rituximab in Patients with Previously Untreated Follicular Lymphoma
[Protocol 14-018]
Palomba, M. Lia, MD
A Phase II Study of Combination Chemotherapy with and without Low-Dose Whole-Brain Radiation for Primary Central Nervous System Lymphoma
[Protocol 11-125]
Omuro, Antonio, MD
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
[Protocol 00-069]
Offit, Kenneth, MD
A Phase II Trial of Transplants from HLA-Compatible Donors with T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System for the Treatment of Patients with Hematologic Malignancies and Disorders
[Protocol 10-050]
O'Reilly, Richard, MD
A Phase I/II Study of the Toxic and Therapeutic Effects of T Cells in the Treatment of Epstein Barr Virus-Associated Lymphoproliferative Disorders
[Protocol 95-024]
O'Reilly, Richard, MD
A Phase II Study Evaluating the Use of Donated EBV-Immune T Cells to Treat Transplant Recipients with EBV
[Protocol 11-130]
O'Reilly, Richard, MD
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLA-Compatible Donor
[Protocol 12-053]
O'Reilly, Richard, MD
A Phase I/II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma
Newly Diagnosed
[Protocol 11-013]
Noy, Ariela, MD
A Pilot Study of AVD plus Brentuximab Vedotin to Treat Stage II-IV HIV-Associated Hodgkin Lymphoma
[Protocol 13-079]
Noy, Ariela, MD
A Phase II Study of Dose-Adjusted EPOCH Chemotherapy with or without Rituximab in Patients with Untreated Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, or Plasmablastic Lymphoma
[Protocol 13-022]
Noy, Ariela, MD
A Study of Bortezomib plus (R)ICE in Subjects with Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Relapsed/Refractory
[Protocol 09-063]
Noy, Ariela, MD
A Phase II Study of Ibrutinib in Patients with Persistent or Recurrent Marginal Zone Lymphoma
[Protocol 14-058]
Noy, Ariela, MD
A Pilot Study of Brentuximab Vedotin with Chemotherapy and Radiation Therapy in Early-Stage Poor-Risk Newly Diagnosed Hodgkin Lymphoma
[Protocol 13-034]
Moskowitz, Craig, MD
A Phase IB Study of MK-3475 in Patients with Myelodysplastic Syndromes and Lymphoma
Relapsed/Refractory
[Protocol 13-220]
Moskowitz, Craig, MD
A Phase I Study of SGN-CD19A in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Relapsed/Refractory
[Protocol 12-282]
Moskowitz, Craig, MD
A Phase III Study of KW-0761 versus Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma
[Protocol 13-007]
Moskowitz, Alison, MD
A Phase I Study of Brentuximab Vedotin plus Temsirolimus in Relapsed and Refractory Hodgkin Lymphoma
Relapsed/Refractory
[Protocol 13-044]
Moskowitz, Alison, MD
Brentuximab (SGN-35) in Transplant-Eligible Patients with Relapsed or Refractory Hodgkin Lymphoma
Relapsed/Refractory
[Protocol 11-142]
Moskowitz, Alison, MD
A Phase I Study of LDK378 in Children with Cancers Containing an ALK Mutation
Relapsed/Refractory
[Protocol 13-235]
Modak, Shakeel, MD
Assessment of Heart Tissue in Survivors of Hodgkin Lymphoma
[Protocol 14-017]
Matasar, Matthew, MD
A Phase I Study of BMS-936558 in Patients with Relapsed or Refractory Hematologic Cancers
Relapsed/Refractory
[Protocol 12-142]
Lesokhin, Alexander, MD
A Study Assessing the Use of Dual Handset Phones to Improve Communication with Inpatients Who Have Limited English Proficiency
[Protocol 14-042]
Kumar, Chhavi, MD
A Phase II Study of KW-0761 or Standard Therapy in Patients with Previously Treated Adult T-Cell Leukemia-Lymphoma
[Protocol 12-251]
Horwitz, Steven, MD
A Phase III Study of Brentuximab Vedotin versus Standard Therapy in Patients with Cutaneous T-Cell Lymphoma
[Protocol 13-008]
Horwitz, Steven, MD
A Study of Physician Communication Skills to Promote Patients' Transition to Survivorship
[Protocol 11-180]
Horwitz, Steven, MD
A Phase III Study of Brentuximab Vedotin plus CHP versus CHOP Therapy for Patients with Previously Untreated CD30-Positive Peripheral T-Cell Lymphoma
[Protocol 13-055]
Horwitz, Steven, MD
PDX-017: A Phase III Study of Pralatrexate Versus Observation in Patients with Peripheral T-Cell Lymphoma Following Initial Chemotherapy
Newly Diagnosed & Relapsed/Refractory
[Protocol 10-212]
Horwitz, Steven, MD
A Phase III Study of Alisertib versus Standard Therapy in Patients with Recurrent or Persistent Peripheral T-Cell Lymphoma
[Protocol 13-180]
Horwitz, Steven, MD
A Phase IB/IIA Study of Romidepsin plus Lenalidomide in Adults with Relapsed or Refractory Lymphoma and Myeloma
Relapsed/Refractory
[Protocol 12-170]
Horwitz, Steven, MD
Ofatumumab with or without Bendamustine for Patients with Mantle Cell Lymphoma Who Cannot Have an Autologous Stem Cell Transplant
Newly Diagnosed
[Protocol 11-050]
Hamlin, Paul, MD
A Phase III Study of Bendamustine and Rituximab with or without Ibrutinib in Older Patients with Newly Diagnosed Mantle Cell Lymphoma
[Protocol 13-196]
Hamlin, Paul, MD